Amifostine is a prodrug that is dephosphorylated to an active ‘free’ thiol metabolite that can reduce the toxic effects of cisplatin.

Amifostine is a prodrug that is dephosphorylated to an active ‘free’ thiol metabolite that can reduce the toxic effects of cisplatin. Pretreatment with amifostine reduces cumulative renal toxicity from cisplatin. Hypotension during amifostine infusion should be minimized by adequately hydrating the patient prior to the infusion. Amifostine infusion should be interrupted if the systolic pressure decreases by more than 20-25% of the baseline reading. Nausea, vomiting and other gastrointestinal effects may be common in patients being treated with amifostine.

 

Indications

  • For reduction of cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced cancer
  • For reduction of moderate to severe xerostomia from radiation of head and neck involving the parotid glands

 

 

Generic Name

Strength

Standard

Type

Packing

Pack Size

Amifostine

500 mg

USP

INJ

Vial

5 ml.